Interaction with PALB2 Is Essential for Maintenance of Genomic Integrity by BRCA2

PLoS Genetics

Volumn 12, Issue 8, 2016, Pages

  Hartford, Suzanne A ^a   Chittela, Rajanikant ^a,c   Ding, Xia ^a   Vyas, Aradhana ^a   Martin, Betty ^b   Burkett, Sandra ^a   Haines, Diana C ^b   Southon, Eileen ^a,b   Tessarollo, Lino ^a   Sharan, Shyam K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANIMAL CELL; APOPTOSIS; ARTICLE; BODY SIZE; CARCINOGENESIS; CONTROLLED STUDY; EMBRYO; FEMALE; GENE; GENE INTERACTION; GENETIC SUSCEPTIBILITY; GENOMIC INSTABILITY; GENOTYPE; HEMIZYGOSITY; HETEROZYGOSITY; HOMOZYGOSITY; MALE; MEIOSIS; MOUSE; NONHUMAN; PALB2 GENE; PHENOTYPE; TRP53 GENE; TUMOR SUPPRESSOR GENE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL; BREAST TUMOR; DNA REPAIR; DOUBLE STRANDED DNA BREAK; GENE TARGETING; GENETIC PREDISPOSITION; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PROTEIN DOMAIN;

BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; APOPTOSIS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOGENESIS; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; FEMALE; GENE KNOCK-IN TECHNIQUES; GENETIC PREDISPOSITION TO DISEASE; GENOMIC INSTABILITY; HUMANS; MICE; MUTATION; NUCLEAR PROTEINS; PROTEIN INTERACTION DOMAINS AND MOTIFS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84984874836     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1006236     Document Type: Article

References (55)

1. West SC, Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol. 2003;4(6):435–45. Epub 2003/06/05. doi: 10.1038/nrm112712778123.
2. Esashi F, Galkin VE, Yu X, Egelman EH, West SC, Stabilization of RAD51 nucleoprotein filaments by the C-terminal region of BRCA2. Nat Struct Mol Biol. 2007;14(6):468–74. Epub 2007/05/23. doi: 10.1038/nsmb124517515904.
3. Davies OR, Pellegrini L, Interaction with the BRCA2 C terminus protects RAD51-DNA filaments from disassembly by BRC repeats. Nat Struct Mol Biol. 2007;14(6):475–83. Epub 2007/05/23. doi: 10.1038/nsmb125117515903; PubMed Central PMCID: PMC2096194.
4. Raghunandan M, Chaudhury I, Kelich SL, Hanenberg H, Sobeck A, FANCD2, FANCJ and BRCA2 cooperate to promote replication fork recovery independently of the Fanconi Anemia core complex. Cell Cycle. 2015;14(3):342–53. Epub 2015/02/07. doi: 10.4161/15384101.2014.98761425659033.
5. Schlacher K, Christ N, Siaud N, Egashira A, Wu H, Jasin M, Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell. 2011;145(4):529–42. Epub 2011/05/14. doi: 10.1016/j.cell.2011.03.04121565612; PubMed Central PMCID: PMC3261725.
6. Lomonosov M, Anand S, Sangrithi M, Davies R, Venkitaraman AR, Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein. Genes Dev. 2003;17(24):3017–22. Epub 2003/12/19. doi: 10.1101/gad.27900314681210; PubMed Central PMCID: PMC305253.
7. Menzel T, Nahse-Kumpf V, Kousholt AN, Klein DK, Lund-Andersen C, Lees M, et al. A genetic screen identifies BRCA2 and PALB2 as key regulators of G2 checkpoint maintenance. EMBO Rep. 2011;12(7):705–12. Epub 2011/06/04. doi: 10.1038/embor.2011.9921637299; PubMed Central PMCID: PMC3128973.
8. Kraakman-van der Zwet M, Overkamp WJ, van Lange RE, Essers J, van Duijn-Goedhart A, Wiggers I, et al. Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol Cell Biol. 2002;22(2):669–79. Epub 2002/01/05. 11756561; PubMed Central PMCID: PMC139737.
9. Wang X, Andreassen PR, D'Andrea AD, Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol Cell Biol. 2004;24(13):5850–62. Epub 2004/06/17. doi: 10.1128/MCB.24.13.5850–5862.200415199141; PubMed Central PMCID: PMC480901.
10. Roy R, Chun J, Powell SN, BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2012;12(1):68–78. Epub 2011/12/24. doi: 10.1038/nrc318122193408.
11. Navarro S, Meza NW, Quintana-Bustamante O, Casado JA, Jacome A, McAllister K, et al. Hematopoietic dysfunction in a mouse model for Fanconi anemia group D1. Mol Ther. 2006;14(4):525–35. Epub 2006/07/25. doi: 10.1016/j.ymthe.2006.05.01816859999.
12. Martinez JS, Baldeyron C, Carreira A, Molding BRCA2 function through its interacting partners. Cell Cycle. 2015;14(21):3389–95. doi: 10.1080/15384101.2015.109370226566862.
13. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. 2006;22(6):719–29. Epub 2006/06/24. doi: 10.1016/j.molcel.2006.05.02216793542.
14. Al Abo M, Dejsuphong D, Hirota K, Yonetani Y, Yamazoe M, Kurumizaka H, et al. Compensatory functions and interdependency of the DNA-binding domain of BRCA2 with the BRCA1-PALB2-BRCA2 complex. Cancer Res. 2014;74(3):797–807. Epub 2013/11/29. doi: 10.1158/0008-5472.CAN-13-144324285729.
15. Siaud N, Barbera MA, Egashira A, Lam I, Christ N, Schlacher K, et al. Plasticity of BRCA2 function in homologous recombination: genetic interactions of the PALB2 and DNA binding domains. PLoS Genet. 2011;7(12):e1002409. Epub 2011/12/24. doi: 10.1371/journal.pgen.100240922194698; PubMed Central PMCID: PMC3240595.
16. Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B, et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol. 2009;19(6):524–9. Epub 2009/03/10. doi: 10.1016/j.cub.2009.02.01819268590; PubMed Central PMCID: PMC2750839.
17. Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497–506. Epub 2014/08/08. doi: 10.1056/NEJMoa140038225099575; PubMed Central PMCID: PMC4157599.
18. Bowman-Colin C, Xia B, Bunting S, Klijn C, Drost R, Bouwman P, et al. Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer. Proc Natl Acad Sci U S A. 2013;110(21):8632–7. Epub 2013/05/10. doi: 10.1073/pnas.130536211023657012; PubMed Central PMCID: PMC3666744.
19. Bouwman P, Drost R, Klijn C, Pieterse M, van der Gulden H, Song JY, et al. Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression. J Pathol. 2011;224(1):10–21. Epub 2011/03/16. doi: 10.1002/path.286121404276.
20. Rantakari P, Nikkila J, Jokela H, Ola R, Pylkas K, Lagerbohm H, et al. Inactivation of Palb2 gene leads to mesoderm differentiation defect and early embryonic lethality in mice. Hum Mol Genet. 2010;19(15):3021–9. Epub 2010/05/21. doi: 10.1093/hmg/ddq20720484223.
21. Biswas K, Das R, Eggington JM, Qiao H, North SL, Stauffer S, et al. Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay. Hum Mol Genet. 2012;21(18):3993–4006. Epub 2012/06/09. doi: 10.1093/hmg/dds22222678057; PubMed Central PMCID: PMC3428152.
22. Oliver AW, Swift S, Lord CJ, Ashworth A, Pearl LH, Structural basis for recruitment of BRCA2 by PALB2. EMBO Rep. 2009;10(9):990–6. doi: 10.1038/embor.2009.12619609323; PubMed Central PMCID: PMC2750052.
23. Park JY, Singh TR, Nassar N, Zhang F, Freund M, Hanenberg H, et al. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair. Oncogene. 2014;33(40):4803–12. doi: 10.1038/onc.2013.42124141787; PubMed Central PMCID: PMC3994186.
24. Orthwein A, Noordermeer SM, Wilson MD, Landry S, Enchev RI, Sherker A, et al. A mechanism for the suppression of homologous recombination in G1 cells. Nature. 2015;528(7582):422–6. doi: 10.1038/nature1614226649820.
25. Buisson R, Dion-Cote AM, Coulombe Y, Launay H, Cai H, Stasiak AZ, et al. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol. 2010;17(10):1247–54. Epub 2010/09/28. doi: 10.1038/nsmb.191520871615; PubMed Central PMCID: PMC4094107.
26. Dray E, Etchin J, Wiese C, Saro D, Williams GJ, Hammel M, et al. Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2. Nat Struct Mol Biol. 2010;17(10):1255–9. Epub 2010/09/28. doi: 10.1038/nsmb.191620871616; PubMed Central PMCID: PMC2950913.
27. Mahadevaiah SK, Turner JM, Baudat F, Rogakou EP, de Boer P, Blanco-Rodriguez J, et al. Recombinational DNA double-strand breaks in mice precede synapsis. Nat Genet. 2001;27(3):271–6. doi: 10.1038/8583011242108.
28. McAllister KA, Houle CD, Malphurs J, Ward T, Collins NK, Gersch W, et al. Spontaneous and irradiation-induced tumor susceptibility in BRCA2 germline mutant mice and cooperative effects with a p53 germline mutation. Toxicol Pathol. 2006;34(2):187–98. Epub 2006/03/21. doi: 10.1080/0192623060061179416546942.
29. Toyooka Y, Tsunekawa N, Takahashi Y, Matsui Y, Satoh M, Noce T, Expression and intracellular localization of mouse Vasa-homologue protein during germ cell development. Mechanisms of development. 2000;93(1–2):139–49. 10781947.
30. Adem C, Soderberg CL, Hafner K, Reynolds C, Slezak JM, Sinclair CS, et al. ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes Cancer. 2004;41(1):1–11. Epub 2004/07/06. doi: 10.1002/gcc.2005715236312.
31. Castro E, Jugurnauth-Little S, Karlsson Q, Al-Shahrour F, Pineiro-Yanez E, Van de Poll F, et al. High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers. Ann Oncol. 2015;26(11):2293–300. Epub 2015/09/09. doi: 10.1093/annonc/mdv35626347108.
32. Holstege H, van Beers E, Velds A, Liu X, Joosse SA, Klarenbeek S, et al. Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers. BMC Cancer. 2010;10:455. Epub 2010/08/26. doi: 10.1186/1471-2407-10-45520735817; PubMed Central PMCID: PMC2940799.
33. Palacios J, Honrado E, Cigudosa JC, Benitez J, ERBB2 and MYC alterations in BRCA1- and BRCA2-associated cancers. Genes Chromosomes Cancer. 2005;42(2):204–5; author reply 6. Epub 2004/11/16. doi: 10.1002/gcc.2012515543618.
34. Nikkila J, Parplys AC, Pylkas K, Bose M, Huo Y, Borgmann K, et al. Heterozygous mutations in PALB2 cause DNA replication and damage response defects. Nat Commun. 2013;4:2578. doi: 10.1038/ncomms357824153426; PubMed Central PMCID: PMC3826652.
35. Park JY, Zhang F, Andreassen PR, PALB2: the hub of a network of tumor suppressors involved in DNA damage responses. Biochimica et biophysica acta. 2014;1846(1):263–75. doi: 10.1016/j.bbcan.2014.06.00324998779; PubMed Central PMCID: PMC4183126.
36. Friedman LS, Thistlethwaite FC, Patel KJ, Yu VP, Lee H, Venkitaraman AR, et al. Thymic lymphomas in mice with a truncating mutation in Brca2. Cancer Res. 1998;58(7):1338–43. Epub 1998/04/16. 9537225.
37. Connor F, Bertwistle D, Mee PJ, Ross GM, Swift S, Grigorieva E, et al. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat Genet. 1997;17(4):423–30. Epub 1997/12/17. doi: 10.1038/ng1297-4239398843.
38. Nikkila J, Parplys AC, Pylkas K, Bose M, Huo Y, Borgmann K, et al. Heterozygous mutations in PALB2 cause DNA replication and damage response defects. Nat Commun. 2013;4:2578. Epub 2013/10/25. doi: 10.1038/ncomms357824153426; PubMed Central PMCID: PMC3826652.
39. Wark L, Novak D, Sabbaghian N, Amrein L, Jangamreddy JR, Cheang M, et al. Heterozygous mutations in the PALB2 hereditary breast cancer predisposition gene impact on the three-dimensional nuclear organization of patient-derived cell lines. Genes Chromosomes Cancer. 2013;52(5):480–94. Epub 2013/01/24. doi: 10.1002/gcc.2204523341105.
40. Donoho G, Brenneman MA, Cui TX, Donoviel D, Vogel H, Goodwin EH, et al. Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice. Genes Chromosomes Cancer. 2003;36(4):317–31. Epub 2003/03/06. doi: 10.1002/gcc.1014812619154.
41. McAllister KA, Bennett LM, Houle CD, Ward T, Malphurs J, Collins NK, et al. Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene. Cancer Res. 2002;62(4):990–4. Epub 2002/02/28. 11861370.
42. Guijarro MV, Ghivizzani SC, Gibbs CP, Animal models in osteosarcoma. Front Oncol. 2014;4:189. Epub 2014/08/08. doi: 10.3389/fonc.2014.0018925101245; PubMed Central PMCID: PMC4102850.
43. Ng AJ, Mutsaers AJ, Baker EK, Walkley CR, Genetically engineered mouse models and human osteosarcoma. Clin Sarcoma Res. 2012;2(1):19. Epub 2012/10/06. doi: 10.1186/2045-3329-2-1923036272; PubMed Central PMCID: PMC3523007.
44. Kovac M, Blattmann C, Ribi S, Smida J, Mueller NS, Engert F, et al. Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency.Nat Commun. 2015;6:8940. doi: 10.1038/ncomms994026632267; PubMed Central PMCID: PMC4686819.
45. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A, Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet. 2001;29(4):418–25. doi: 10.1038/ng74711694875.
46. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A, Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev. 1997;11(10):1226–41. Epub 1997/05/15. 9171368.
47. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG, Simple and highly efficient BAC recombineering using galK selection. Nucleic acids research. 2005;33(4):e36. doi: 10.1093/nar/gni03515731329; PubMed Central PMCID: PMC549575.
48. Tessarollo L, Manipulating mouse embryonic stem cells. Methods Mol Biol. 2001;158:47–63. 11236671.
49. Meyers EN, Lewandoski M, Martin GR, An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination. Nat Genet. 1998;18(2):136–41. 9462741.
50. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature. 1997;386(6627):804–10. Epub 1997/04/24. doi: 10.1038/386804a09126738.
51. Reinholdt LG, Munroe RJ, Kamdar S, Schimenti JC, The mouse gcd2 mutation causes primordial germ cell depletion. Mechanisms of development. 2006;123(7):559–69. doi: 10.1016/j.mod.2006.05.00316822657.
52. Kuznetsov SG, Liu P, Sharan SK, Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2. Nature medicine. 2008;14(8):875–81. doi: 10.1038/nm.171918607349; PubMed Central PMCID: PMC2640324.
53. Reinholdt L, Ashley T, Schimenti J, Shima N, Forward genetic screens for meiotic and mitotic recombination-defective mutants in mice. Methods Mol Biol. 2004;262:87–107. doi: 10.1385/1-59259-761-0:08714769957.
54. Ray Chaudhuri A, Hashimoto Y, Herrador R, Neelsen KJ, Fachinetti D, Bermejo R, et al. Topoisomerase I poisoning results in PARP-mediated replication fork reversal. Nat Struct Mol Biol. 2012;19(4):417–23. doi: 10.1038/nsmb.2258.22388737.
55. Jackson DA, Pombo A, Replicon clusters are stable units of chromosome structure: evidence that nuclear organization contributes to the efficient activation and propagation of S phase in human cells. The Journal of cell biology. 1998;140(6):1285–95. 9508763; PubMed Central PMCID: PMC2132671.